# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001171843-20-002184
Filing Date
2020-03-31
Accepted
2020-03-31 12:52:25
Documents
4
Period of Report
2020-05-12
Effectiveness Date
2020-03-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFINITIVE PROXY STATEMENT | def14a_033120.htm | DEF 14A | 962273
2 | GRAPHIC | logo.jpg | GRAPHIC | 5374
3 | GRAPHIC | proxy_1.jpg | GRAPHIC | 1782316
4 | GRAPHIC | proxy_2.jpg | GRAPHIC | 958511
| Complete submission text file | 0001171843-20-002184.txt |  | 4745425

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-23186 | Film No.: 20760699
SIC: 2836 Biological Products, (No Diagnostic Substances)